What is ImmunoSite Technologies?
ImmunoSite Technologies, LLC operates as a premier global provider of contract research and development services. The company specializes in automation, particle characterization, and product development support tailored for the pharmaceutical, bio-pharma, and biotech sectors. By offering customized solutions that adhere to stringent FDA and EPA requirements, ImmunoSite Technologies ensures high-quality service delivery, underscored by its ISO 9001 and ISO 13485 certifications. Its client base spans contract research organizations, clinical research centers, government agencies, and various manufacturers. The company's core mission is to enhance productivity and efficiency within the life sciences industry through a commitment to quality and personalized client care.
How much funding has ImmunoSite Technologies raised?
ImmunoSite Technologies has raised a total of $34K across 1 funding round:
Debt
$34K
Debt (2021): $34K with participation from PPP
What's next for ImmunoSite Technologies?
With the recent substantial expansion capital, ImmunoSite Technologies is poised for significant growth and enhanced service capabilities. This strategic investment is expected to fuel advancements in their automation and particle characterization technologies, potentially expanding their R&D service offerings. The company's focus on meeting regulatory standards and its established client relationships suggest a trajectory towards increased market penetration and the development of innovative solutions for the life sciences sector. Future developments may include strategic partnerships or acquisitions to further solidify its position as a leader in contract R&D services.
See full ImmunoSite Technologies company page
